Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 2003

View Archived Issues

New studies on atomoxetine presented at the APA meeting

TSU-68 active in patients with advanced solid tumors

CEP-701 reported to induce antitumoral effects in refractory AML

Good toxicity profile for CEP-7055 in patients with incurable solid tumors

Evidence of antitumor effects reported for ZD-6474 in refractory solid tumors

New PAF antagonists and their use as neuroprotectants described in recent patent

Pfizer claims novel protein kinase C inhibitors for use in pain, diabetic neuropathy, etc.

New antimicrobial carbapenems under study at Sumitomo

New factor Xa inhibitors, their preparation and use claimed by Kissei scientists

Maruha researchers identify new antagonists of Edg receptors

Novel EP2 receptor agonists with utility in glaucoma therapy discovered at Allergan

Schering-Plough researchers prepare and test new ORL-1 receptor agonists

New PPARgamma receptor modulators in Sankyo development pipeline

ImClone and BMS discuss Erbitux regulatory filing with FDA

GlaxoSmithKline advances development of GW-501516

Generex proposes acquisition of Antigen Express

Fujisawa and GSK sign U.S. copromotion agreement for Protopic

Ganymed and U. of Ghent come together for target validation

Roche's option to Vernalis A2A antagonist program in depression terminated

Dosing under way in phase II catheter occlusion trial of alfimeprase

Pivotal Actiza trial completes enrollment

Manufacturing of CoFactor underway

Enrollment completed in phase III alvimopan study in postoperative ileus

Nabi receives complete response for Nabi-HB

Medicure advances MC-4232 towards phase II/III

Grupo Vita signs marketing agreement for Eneas covering Turkey and Greece

Enrollment concluded in supportive phase III trial of Surfaxin for RDS

Phase III trial update on six-month Eligard product

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...